晚期心力衰竭患者的甲状腺功能障碍及其与阿米奥达龙治疗的相关性:为期两年的研究
Agnieszka Kuczaj1,2, Szymon Warwas1, Anna Danel3
1Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Biomedicines
|March 28, 2024
概括
甲状腺功能障碍在晚期心力衰竭患者中很常见,而阿米奥达龙的使用是一个重要的因素. 然而,这种甲状腺问题并没有增加研究组的死亡率.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期心力衰竭经常表现为心室心律不整,往往需要抗心律不整治疗.
- 阿米奥达龙是一种常见的抗心律失常药,含有高水平的,可以诱导甲状腺功能障碍.
- 在末期心力衰竭中,阿米奥达龙诱导的甲状腺功能障碍的患病率和特定关联尚未得到充分确立.
研究的目的:
- 确定晚期心力衰竭患者甲状腺功能障碍的患病率和类型.
- 在这个队列中调查阿米奥达龙治疗与甲状腺功能障碍之间的关联.
- 评估甲状腺功能障碍对晚期心力衰竭患者死亡率的影响.
主要方法:
- 一项为期两年的随访研究,对200名心力衰竭晚期患者进行了随访,这些患者有资格接受移植.
- 评估甲状腺功能和与阿米奥达龙使用的相关性.
- 根据欧洲心脏病学会指南分析患者数据.
主要成果:
- 在61名患者 (30.5%) 观察到甲状腺功能障碍,女性更频繁.
- 诊断出甲状腺功能障碍 (34名患者) 和甲状腺功能障碍 (27名患者).
- 在阿米奥达龙使用和甲状腺功能障碍之间发现了显著的相关性,但并没有增加死亡率.
结论:
- 甲状腺功能障碍在晚期心力衰竭中很普遍,而阿米奥达龙是其中的一个因素.
- 在这种患者群体中,甲状腺功能障碍似乎与较高的死亡率无关.
- 需要进行进一步的研究,以优化耐心心力衰竭患者甲状腺功能障碍的管理.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
988
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
988
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K